New drug GB18 targets wasting in cancer patients – first human trial launches
NCT ID NCT07237464
First seen Nov 19, 2025 · Last updated May 14, 2026 · Updated 20 times
Summary
This early-stage trial tests a new drug called GB18, designed to treat cancer cachexia—a condition where cancer patients lose weight and muscle. The study involves 36 healthy adults to check the drug's safety and how the body processes it. Participants receive a single injection of GB18 or a placebo, and researchers monitor side effects and drug levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER CACHEXIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.